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Abstract 
BACKGROUND: Individuals, during opioid withdrawal period, experience symptoms such as dysphoria, insomnia, 
anxiety, irritability, nausea, agitation, tachycardia, and hypertension which may trigger drug seeking behavior and 
relapse. This study was conducted with the aim of determining the effect of Tranquival tablets on some heroin 
withdrawal symptoms in addicted patients referred to an outpatient clinic. 
METHODS: In this single-blind quasi-experimental study, 69 patients (37 patients in intervention group and 32 in 
control group) suffering from heroin withdrawal syndrome were allocated randomly to study groups. In the 
intervention group, 1 Tranquival tablet was administered 1 hour before sleeping each night for 6 weeks. In the 
control group, 1 tablet of clonazepam (1 mg) was administered at the same time. The Pittsburgh Sleep Quality 
Index (PSQI), Hamilton Anxiety Rating Scale (HAM-A), and visual analogue scale (VAS) were completed at the 
beginning, 3 weeks later, and the end of the study. Data were analyzed using Student’s t-test, repeated measures 
analysis, and chi-square test. 
RESULTS: During the study period in both groups, withdrawal symptoms significantly decreased (P < 0.001); 
however, this difference was insignificant between the 3 assessment steps (P > 0.050). Furthermore, the 
Bonferroni correction showed an relationship between Tranquival and clonazepam groups in terms of mean anxiety 
at the begining and the end stage of assessment (P = 0.012). However, these relationships were insignificant in 
terms of mean sleep and muscular pain (P = 0.153 and P = 0.267, respectively). 
CONCLUSION: Tranquival was as effective as clonazepam in the reduction of muscular pain and anxiety, and 
improvement of sleep quality in patients suffering from heroin withdrawal syndrome. 
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Introduction1 
Heroin is one of the most commonly used 
drugs among drug users in both developed and 
developing countries. Methadone maintenance 
treatment (MMT) has been found to be an 
effective harm reduction program for drug 
users.1 Methadone is a long-acting synthetic 
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opioid with high attraction to various opioid 
receptors and has been used as a successful 
pharmacologic treatment for patients with 
heroin dependency, and acute and chronic 
pain.2 However, there are few studies which 
comparatively examined the development and 
course of withdrawal symptoms in opiate 
addicts in response to such detoxification 
procedures.3 Individuals, during the opioid 
withdrawal period, experience symptoms such 
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as dysphoria, insomnia, anxiety, irritability, 
nausea, agitation, tachycardia, and 
hypertension which may trigger drug-seeking 
behavior and relapse.4 
Drugs such as benzodiazepines are 
administered in the treatment of heroin 
withdrawal symptoms.5 In MMT programs, 
patients who are addicted to benzodiazepine 
are at risk for polydrug abuse.6 Most patients 
relapse to opioids within one month of opioid 
agonist detoxification; therefore, there is low 
rate of completion of detoxification.7 Some 
evidence indicates that drugs which are often 
used to treat anxiety and insomnia have 
adverse effects that are related to acquired 
tolerance and withdrawal from the drug.8,9 
Today, herbal remedies are a popular form 
of therapy and have been developed as 
alternative methods of inducing calming 
effects.10 Tranquival is an herbal product which 
consists of valerian, Passiflora, Melissa 
officinalis, and Humulus lupulus. The efficacy 
of its ingredients in different disorders has 
been previously demonstrated. Passiflora is 
effective on treating nervous restlessness, sleep 
disorders, nervous stress, generalized anxiety 
disorder (GAD), symptoms of opiate 
withdrawal, insomnia, neuralgia, convulsion, 
spasmodic asthma, attention deficit 
hyperactivity disorder (ADHD), palpitations, 
cardiac arrhythmia, hypertension, sexual 
dysfunction, and menopause.11-16 Valeriana 
officinalis L. is a member of the Valerianaceae 
family with hypnotic,17 anxiolytic,18 
antidepressant, and myorelaxant properties.19 
Melissa officinalis L. (lemon balm) is used in 
traditional medicine to treat insomnia, anxiety, 
gastric conditions, psychiatric conditions, 
migraine, hypertension, mild to moderate 
bronchial conditions, and sleep disturbances.20,21 
Humulus lupulus L. (hop) is well known 
throughout the world, and is used as a mild 
sedative and activator of gastric function.22 
Despite the increasing interest in natural 
and complementary therapies for substance 
use disorders, clinical studies in this area are 
limited and there are insufficient documents to 
support the use of these therapies for opiate 
withdrawal symptoms. The present study was 
conducted with the aim of determining the 
effect of Tranquival on some opiate 
withdrawal symptoms in heroin addicted 
patients in the detoxification phase. 
Materials and Methods 
This study was conducted in an addiction 
treatment clinic, in Shahrekord, Iran (from 
June 2012 until October 2012). The Ethics 
Committee of Shahrekord Univeristy of 
Medical Sciences, Shahrekord, approved the 
study protocol and the study was registered in 
the Iranian Clinical Trial Center (IRCT) by 
IRCT201306222085N10. 
Written informed consents were obtained from 
all patients before entering the study. A 
psychiatrist visited all patients and carried out the 
diagnosis of opioid withdrawal. This psychiatrist 
prescribed Tranquival or clonazepam for the 
patients in different study groups.  
In this quasi-experimental study, the 
participants consisted of 80 males with a 
history of heroin addiction. The participants 
fulfilled the criteria for opioid dependency and 
withdrawal syndrome of the Diagnostic and 
Statistical Manual of Mental Disorders, 4th 
Edition, Text Revision (DSM-IV-TR). All 
subjects were outpatients who referred to an 
addiction treatment clinic. Inclusion criteria 
consisted of age of 20 to 50 years, a history of 
heroin use of at least 2 years (0.5 to 1 gr/day), 
suffering from withdrawal syndrome, 
receiving methadone treatment (30 to 60 
mg/day), lack of allergy to Passiflora, 
Valeriana officinalis, Humulus lupulus, and 
Melissa officinalis, and referring to an 
addiction treatment clinic. Exclusion criteria 
consisted of psychiatric disorders or history of 
hospitalization in a psychiatric ward, 
unwillingness to participation in the study, 
and occurrence of any side effects related to 
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Tranquival consumption. In addition, patients 
who used opioids or drugs without the 
prescription of a psychiatrist were excluded 
from the study.  
A number was given to each patient, then, 
according to their odd or even numbers, they 
were randomly assigned to Tranquival (n = 40) 
or clonazpam (n = 40) groups. 
In the present study, a general physician 
who was not aware of the patients’ groups 
completed the study questionnaires; thus, this 
study was a single-blind study. In addition, 
regarding to the different shapes of Tranquival 
and clonazepam tablets, the patients were 
aware of their medication type. 
In the Tranquival (intervention) group, the 
patients took 1 tablet of Tranquival (Dineh Iran 
Co., Iran) orally an hour before sleep every 
night for 6 weeks. The ingredients of the 
Tranquival tablet are 150 mg Valeriana 
officinalis, 100 mg Passiflora incarnata, 50 mg 
Humulus lupulus, and 50 mg Melissa 
officinalis. In the clonazepam (control) group, 
the patients took 1 mg of clonazepam (Arya 
Co., Iran) orally an hour before sleep every 
night for 6 weeks. 
The data collection tools consisted of the 
Pittsburgh Sleep Quality Index (PSQI), 
Hamilton Anxiety Rating Scale (HAM-A), 
and visual analogue scale (VAS) for 
muscular pain assessment. The 
questionnaires were completed in 3 steps; at 
the beginning of the study (T1), and 3 (T2) 
and 6 weeks later (T3). The PSQI is a 
standardized self-administered 
questionnaire. Its reliability and validity 
have been approved for patients with 
psychiatric disorders, sleep disturbance, and 
other somatic diseases.23 The PSQI consists of 
7 clinically derived components that assess 
sleep difficulty, and the sum of these 
component scores yields a global score of 
subjective sleep quality (range: 0–21). The 
reliability and validity of the Persian version 
of the PSQI (PSQI-P) were assessed by 
Farrahi et al.24 In the study by Farrahi et al., 
the sensitivity and specificity of 
discrimination of patients with insomnia 
from control subjects was 94% and 72% for a 
PSQI cut-off value of 5, and 85% and 84% for 
a PSQI cut-off value of 6, respectively. The 
psychometric properties of the PSQI-P are 
acceptable.24 
The HAM-A is one of the first rating scales 
developed to measure the severity of anxiety 
symptoms, and is widely used in both clinical 
and research setting. The scale consists of 14 
items, each defined by a series of symptoms, 
and measures of both psychic and somatic 
anxiety. The HAM-A is widely used as an 
outcome measure in clinical trials. The 
reported levels of reliability for the scale are 
acceptable. Each item is scored on a scale of 0 
(not present) to 4 (severe), with a total score 
range of 0–56. A score of lower than 17 
indicates mild severity, 18–24 mild to 
moderate severity, and 25–30 moderate to 
severe.25 This scale was used in an Iranian 
study.13 HAM-A consists of 14 factors. A 
validity of 75% and reliability of 85% has been 
reported for this scale by Divsalar et al.26 
The reliability of the VAS for acute pain 
measurement is high and the VAS is 
sufficiently reliable in the assessment of acute 
pain.27 The VAS is a self-report questionnaire. 
The respondent is asked to place a line 
perpendicular to the VAS line at the point that 
represents their pain intensity. In clinical 
practice, the percentage of pain relief which is 
assessed by VAS is considered as a measure of 
the efficacy of treatment. A higher score 
indicates greater pain intensity. The reliability 
and validity of the VAS for disability in 
patients with chronic musculoskeletal pain has 
been evaluated by Boonstra et al.27 
In the present study, data were statistically 
analyzed using SPSS software (version 16, SPSS 
Inc., Chicago, IL, USA) and Student’s t-test, 
repeated measures analysis (Bonferroni 
correction), and chi-square test. 
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Results 
There were no significant differences between 
the two study groups in terms of the history of 
addiction in close family members, educational 
level, economic status, occupation, marital 
status, age, and heroin dependency period 
(Table 1). Over the course of the trial, 3 subjects 
dropped out from the Tranquival group and 8 
from the clonazepam group. Therefore, 37 
patients in the Tranquival group and 32 in the 
clonazepam group completed the trial (Figure 1). 
 
Table 1. Demographic characteristics of patients in the two study groups 
Variables Tranquival group Clonazepam group P 
Occupation Employed 20 20 0.62 
Unemployed 17 12 
Marital status Single 13 8 0.43 
Married 24 24 
History of addiction in family  No 24 16 0.23 
Yes 13 16 
Education  Illiterate 16 10 0.28 
Primary school 16 13 
Middle and high school 5 9 
Economic status Sufficient 16 10 0.33 
Insufficient 21 22 
Age (year) 31.40 ± 8.30 34.80 ± 8.00 0.09 
Heroin dependency period (year) 3.62 ± 1.44 3.25 ± 0.95 0.20 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow chart of study participants 
10 participants did not 
permit randomization. 
Tranquival group = 40 
3 were excluded due to 
lack of cooperation in 
treatment by Tranquival. 
Clonazepam group = 40 
8 were excluded due to 
consumption of heroin. 
32 participants 
150 addicted patients were evaluated. 
80 addicted patients 
40 patients reported a psychiatric disorder or 
history of hospitalization in a psychiatric 
ward, 20 were not interested in participation 
in the study, and 10 were allergic to herbal 
drugs.  
 
32 participants 
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Table 2. Comparison of the anxiety, quality of sleep, and muscular pain scores in different stages of the 
study among the two groups 
Symptom Stage of assessment Tranquival group (mean ± SD) Clonazepam group (mean ± SD) 
Anxiety Before 23.9 ± 8.2 23.8 ± 8.1 
3 Weeks later 15.4 ± 6.6 17.0 ± 7.9 
6 Weeks later 13.0 ± 7.4 15.8 ± 7.7 
Sleep Before 14.2 ± 3.3 14.5 ± 3.3 
3 Weeks later 8.2 ± 3.1 9.7 ± 4.0 
6 Weeks later 7.4 ± 3.5 9.1 ± 4.5 
Muscular pain Before 51.0 ± 31.0 47.1 ± 30.7 
3 Weeks later 38.0± 28.8 34.3 ± 27.0 
6 Weeks later 28.4 ± 25.5 31.0 ± 25.4 
Mean anxiety, sleep disorder, and muscular pain in both groups showed a descending trend (P < 0.001) 
There was no significant differences between the two groups in the 3 assessment stages in terms of mean anxiety, sleep disorder, and 
muscular pain (P > 0.05); SD: Standard deviation 
 
 
Figure 2. Comparison of the quality of sleep score in different stages of the study  
among the two groups 
 
 
Figure 3. Comparison of muscular pain score in different stages of the study  
among the two groups 
Tranquival Group 
Tranquival Group 
Clonazepam Group 
Clonazepam Group 
Tranquival Group 
Clonazepam Group 
Tranquival Group 
Clonazepam Group 
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Figure 4. Comparison of the anxiety score in different stages of the study among the two groups 
 
During the study period, in both groups, 
withdrawal symptoms (sleep, anxiety, and 
muscular pain) significantly decreased  
(P < 0.001) (Table 2); however, this difference 
was insignificant in the 3 assessment steps  
(P > 0.050). Furthermore, Bonferroni correction 
showed a relationship between Tranquival and 
clonazepam groups in mean anxiety at the 
beginning and the end stage of assessment  
(P = 0.012). Nevertheless, these relationships 
were insignificant in terms of mean sleep and 
muscular pain (P = 0.153 and P = 0.267, 
respectively) (Figures 2-4). 
In both groups, patients reported 
drowsiness, but the rate of this side effect was 
higher in the clonazepam group (3 in 
Tranquival vs. 9 in clonazepam group). In 
addition, 3 patients in the clonazepam group 
had amnesia. 
Discussion 
This study showed that Tranquival was as 
effective as clonazepam in the treatment of some 
withdrawal symptoms in patients with heroin 
addiction in the detoxification phase. In addition, 
patients in the Tranquival group reported fewer 
side effects and greater compliance in 
comparison to the clonazepam group. 
Treatment with benzodiazepines may 
reduce complaints of pain, but this seems to be 
an indirect effect related to their psychotropic 
properties, such as alleviation of anxiety and, 
in selected cases, depression. Clinical 
experience has shown benzodiazepines to be 
effective in the treatment of acute muscle 
spasm, concomitant chronic pain and anxiety, 
and lancinating neropathic pain, in which case 
clonazepam and alprazolam may be the agents 
of choice.28 
Although a limited number of clinical 
studies have been performed on the 
effectiveness of Tranquival in treatment of 
opiate detoxification and withdrawal 
syndrome, each ingredient of Tranquival has 
anxiolytic effects. Melissa officinalis, Humulus 
lupulus (hops), valerian, and Passiflora 
incarnata inhibit γ-aminobutyric acid (GABA) 
catabolism.12,29,30 
Miroddi et al., in a bibliographic 
investigation, found that the genus Passiflora 
incarnata has been used to cure subjects 
affected by opiate dependence in India.31  b 
Tranquival Group 
Clonazepam Group 
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and Conduit, suggested that the consumption 
of a low dose of Passiflora incarnata is effective 
in the treatment of mild sleep fluctuations in 
healthy adults.15 Akhondzadeh et al. found 
Passiflora to be effective in the treatment of 
physical symptoms related to opiates 
withdrawal syndrome.13 The numerous 
pharmacological effects of Passiflora incarnata 
are mediated via modulation of the GABA 
system, including affinity to GABAA and 
GABAB receptors and effects on GABA 
uptake.14 In addition, valerian extract 
(valepotriates) has a potential anxiolytic effect 
on the psychic symptoms of anxiety. 
Andreatini et al. suggested that valepotriates 
have a potential anxiolytic effect on the psychic 
symptoms of anxiety.32 
On the other hand, Melissa officinalis is 
effective on the treatment of anxiety and sleep 
disturbances. Guginski et al. found that 
Melissa officinalis (lemon balm) extract 
produced dose-related antinociceptive effect in 
several models of chemical pain with 
cholinergic mechanisms and the L-arginine-
nitric oxide pathway. The rosmarinic acid in 
this plant contributes to its antinociceptive 
effect.33 
The sedative effects of Humulus lupulus L. 
(hops) extract result mainly from its bitter 
acids, and in particular their oxidative 
degradation products such as that resulting 
from the α-acid content (2-methyl-3-buten-2-
ol).34 The main mechanism of action of hops is 
increasing the activity of the GABA 
neurotransmitter through modulation of brain 
GABA (A) receptors. The sedative effect of 
hops on the nervous system has been widely 
reported in animal research, as also has its 
narcotic effect at high concentrations due to  
2-methyl-3.35 Park et al., in their study, 
suggested that hop extract has an 
antinociceptive property in various pain 
models. Furthermore, the antinociceptive effect 
of hop extract may be mediated by opioidergic 
receptors.35 
Furthermore, studies have shown that the 
combination of these herbs are effective in the 
treatment of anxiety and sleep disturbance. 
Kennedy et al. approved the anxiolytic effect of 
the combination of Melissa officinalis and 
valerian.36 In addition, Wahling et al. showed 
that the combination of valerian, hops, and 
passion flower can increase sleep quality.37. 
Conclusion 
Regarding the effectiveness of Tranquival in 
reduction of some withdrawal symptoms in 
heroin addicted patients in the detoxification 
phase and its fewer side effects in comparison 
to clonazepam, researchers suggested that this 
tablet be used in the treatment of heroin 
withdrawal symptoms. The efficacy of 
Tranquival may be related to different 
properties of its ingredients. However, further 
studies should be undertaken to determine the 
efficacy and the mechanism of action of 
Tranquival on withdrawal syndrome. 
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